本页面由Tiger Trade Technology Pte. Ltd.提供服务

Syntara Ltd

0.031
-0.001-3.13%
成交量:258.44万
成交额:8.02万
市值:5,060.44万
市盈率:-4.28
高:0.032
开:0.032
低:0.031
收:0.032
52周最高:0.089
52周最低:0.023
股本:16.32亿
流通股本:10.05亿
量比:6.82
换手率:0.26%
股息:- -
股息率:- -
每股收益(TTM):-0.007
每股收益(LYR):-0.005
净资产收益率:-90.51%
总资产收益率:-47.51%
市净率:4.77
市盈率(LYR):-5.75

数据加载中...

公司资料

公司名字:
Syntara Ltd
交易所:
ASX
成立时间:
1998
员工人数:
- -
公司地址:
20A Rodborough Road,Unit 2,Frenchs Forest,New South Wales,Australia
邮编:
2086
传真:
61 2 9451 3622
简介:
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, pulmonary fibrosis, liver, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO/MPO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.